Hi:
I am seeing a new Doc who thinks my ME/CFS may be related to auto-immune issues. Many of you know who this Dr is and some of you have had success with his treatments. I will be having his myriad of testing done and from that point we will try to develop a plan of action.
I have been severely ill for 10+ years.....bedbound the last 6-7. I have debilitating fatigue, unrefreshing sleep, severe NMH, HPA dysfunction, EDS....etc. The only area I am lucky in this disease is my cognition is not severely affected, more moderate. The worst things are inability to sleep well and inability to stand more than 5-10mins b/c of severe NMH.
Anyway, if results come in as Doc expects we may be looking at IVIG and ritux treatment. I know several of you have had success with this approach. I am wondering if ppl who have tried this approach wld be willing to share their experiences. Have you improved? Have some gotten worse with this treatment?
I am very gun shy but also desperate. Every treatment I have tried has either made me worse or had no affect at all.
I know this is a very broad question, but I am too ill to make it more precise. Any feedback received is greatly appreciated.
Warmest Regards to Everyone!
Hi
@Navid . Thanks for starting this interesting thread. A number of the well-known UK ME experts from some years ago, found that the treatment was effective, sometimes very effective in some patients.
I have this document in my files and you may find something of interest in it. (My computer won't let me upload it so I hope it is readable it I paste in here>
‘
TREATMENTS WITH ‘SCIENTIFICALLY PROVEN VALUE FOR CFS’
SUPPORTING REFERENCES
The diagnosis, treatment and management of chronic fatigue syndrome (CFS) / myalgic encephalomyelitis (ME) in adults and children: work to support the NICE Guidelines;
Anne-Marie Bagnall, Susaznne Hempel, Duncan Chambers, Vickie Orton, and Carol Forbes; Centre for Reviews and Dissemination, University of York,
October 2005.
According to this review,
published evidence supporting the efficacy of immunological interventions comprises:
IMMUNOLOGICAL
164. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-8.
168. See DM, Tilles JG.
alpha-Interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996;25:153-64.
169. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P,
et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18 Suppl 1:S88-95.
173. Andersson M, Bagby JR, Dyrehag L, Gottfries C.
Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. Eur J Pain 1998;2:133-42.
174. Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG.
Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial. Eur J Pain 2002;6:455-66.
175. Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM
. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine. J Chronic Fatigue Syndr 2003;11:71-93.
216.
DESCRIPTION FROM ‘YORK REVIEW’ (refs below)
Immunoglobulins
Three RCTs of participants diagnosed with CFS investigated the effects of immunoglobulin in adults; two found some positive effect, and the third found no effect of treatment.
(I) Trial 164 One RCT found greater improvements in the intervention group on symptom scores and functional capacity but not in depression, immune outcomes or quality of life. [164]
Withdrawals: 2 immunoglobulin recipients withdrew from study: one because of mild, but transient, abnormal liver function tests, other withdrew voluntarily after phlebitis had occurred with the first infusion
Adverse events: Phlebitis and constitution symptoms including headaches, worsened fatigue and concentration impairment occurred more commonly in the immunoglobulin recipients than in the patients who received placebo. Phlebitis occurred in 35/65 immunoglobulin infusions & with 1 placebo infection, constitutional symptoms occurred in 53/65 immunoglobulin infusions and 19/78 placebo infusions.
(II) Trial 165 A second smaller RCT found improved immune measurements (physiological outcome) but not functional or symptom measures. [165]
(III) Trial 166 A third RCT, which was the largest in the immunoglobulin category, found no improvement in any of the outcomes investigated (functional status, mood, immune outcomes and quality of life). [166]
QUERY – see below
(IV) Trial 216 One RCT of immunoglobulin G included only children [216] A significant improvement in functional score (based on attempts and attendance at school or work and physical or social activities) was reported in the intervention group compared to the control group. Significantly more children in the intervention group had an improvement in score of 25% or more. (No participants dropped out due to adverse effects)
(I) and (II) Trials 166 and 164 A second RCT of immunoglobulin included both adults and children according to standard definitions, although no participants under the age of 16 were included. [166] Significant improvements were seen in symptom scores and in functional capacity in the intervention group compared to the control group. THIS WOULD APPLY TO 164 ALSO
Adverse Effects Some severe adverse effects were noted in participants in the immunological intervention groups. … two people from immunoglobulin treatment due to severe constitutional symptom reactions. [166] One recipient of immunoglobulin therapy also withdrew due to mild but transient liver failure [164] and phlebitis has also been noted with immunoglobulin infusions. [164]
Summary Four RCTs assessed the effects of immunoglobulin in patients with CFS, of these one showed an overall beneficial effect [216] one showed some positive effects [164], and two found no effect. [165, 166] All four of these RCTs scored reasonably well on the validity assessment, achieving scores of between 13 and 16 out of 20.
164. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.
Am J Med 1990;89:561-8.
165. Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.
Am J Med 1990;89:554-60.
166. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome.
Am J Med 1997;103:38-43
216. Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents.
J Psychiatr Res 1997;31:133-47.
See also Question 2 studies – Bates (115), Miller (109),
See also Lloyd immunoglobulin & CBT study
Staphylococcus Toxoid
The effects of vaccination with staphylococcus toxoid were investigated in one small controlled trial of patients with CFS (n=28) [173] and one fairly large RCT (n=98) [174]. In the controlled trial, no differences were reported in depression, pain or psychological outcomes between the intervention and control group. However, a greater improvement in the clinical global impression in the treatment group was found. In the RCT, the treatment group had a significantly better outcome than the control group for global impression and one item on the fibromyalgia impact questionnaire.
A positive effect was found in one small controlled trial of staphylococcus toxoid [173] and one larger RCT [174]
Re the 2002 Review:
The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children. A Bagnall
et al. NHS Centre for Reviews and Dissemination, University of York, September 2002.
This review of research findings, commissioned by the CMO’s Working Group, identified a total of 21 interventions – grouped under the categories immunological, antiviral, pharmacological, supplements, complimentary/alternative, behavioural, and ‘other’ – which showed some evidence of effectiveness in controlled trials.
§ From among this group, behavioural interventions have risen to prominence because of the
number of trials conducted, this reflecting their relatively greater success in securing funding.
§ Other interventions have indeed shown evidence of efficacy, but mostly in a smaller number of studies.
It is notable that use of the immunological agent Immunoglobulin G, which demonstrated effectiveness in three out of four randomised controlled trials (seep45) receives no mention at all in the discussion of therapeutic strategies in the Working Group Report.
[1] NB This is exactly the same incidence as pertained to CBT Trials at this point.
[1] A Report of the CFS/ME Working Group: Report to the Chief Medical Officer of an Independent Working Group. London: Department of Health, 2002, pages 45-51.